Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL1155257 | 0.86 | CTDSP1 (0.43) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA | |
| SCHEMBL1024401 | 0.86 | — | — | |
| Ethaneperoxoic Acid SCHEMBL7599452 | 0.86 | CTDSP1 (0.35) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA | |
| Bicarbonate SCHEMBL9573734 | 0.79 | CTDSP1 (0.42) | CTDSP1APOBEC3AAPOBEC3GFFAR3L3MBTL1 | |
| Acetic Acid Phenyl Ester SCHEMBL8861212 | 0.78 | ELANE (0.44) | LMNACYP2C19RAB9ASMN1; SMN2ALDH1A1 | |
| Hydrogen Peroxide SCHEMBL9196247 | 0.76 | CTDSP1 (0.46) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA | |
| SCHEMBL11965867 | 0.75 | ALOX15 (0.36) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1HIF1A | |
| SCHEMBL16779993 | 0.73 | CTDSP1 (0.36) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA | |
| SCHEMBL9752099 | 0.73 | CTDSP1 (0.36) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA | |
| SCHEMBL31338805 | 0.73 | CTDSP1 (0.36) | CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | RHYTHM PHARMACEUTICALS INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20240190914-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2001092292-A2 | GHRELIN ANALOGS | MERCK & CO., INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-0402881-B1 | Process for improving the coefficient of traction. | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-5126065-A | PROCESS FOR IMPROVING THE COEFFICIENT OF TRACTION AND TRACTION DRIVE FLUID | IDEMITSU KOSAN CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0402881-A1 | Process for improving the coefficient of traction. | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-12-19 | — | — | EP | disclosed |
| US-4091020-A | CONDENSATION, CATALYTIC DECARBOXYLATION | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4065497-A | MICROBIOCIDES, ALGICIDES | MERCK & CO., INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-4058625-A | Broad spectrum antimicrobial compositions containing tris-(hydroxymethyl)aminomethane and polyamines | MERCK & CO., INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4035174-A | MICROBIOCIDES | MERCK & CO., INC. (US) | 1977-07-12 | — | — | US | disclosed |
| US-4033748-A | MICROBIOCIDES | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-4003934-A | ANTIMICROBIAL AGENTS, ALGAE INHIBITORS | MERCK & CO., INC. (US) | 1977-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082717-A1 | COMPOSITIONS FOR TREATING KIDNEY DISEASE | MC4R, MC2R, MC5R | CTDSP1 4255/4885APOBEC3A 4325/4885APOBEC3G 3466/4885 |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | CTDSP1 3704/4885APOBEC3A 4071/4885APOBEC3G 3875/4885 |
| US-12263202-B2 | Method of treating melanocortin-4 receptor pathway-associated disorders | MC4R, MC5R, MC3R | CTDSP1 3924/4885APOBEC3A 3516/4885APOBEC3G 3549/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | CTDSP1 4746/4885APOBEC3A 2950/4885APOBEC3G 2009/4885 |
| US-20240190914-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | MC4R, MC1R, MC2R | CTDSP1 3518/4885APOBEC3A 2835/4885APOBEC3G 2840/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | CTDSP1 2977/4885APOBEC3A 2093/4885APOBEC3G 1178/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | CTDSP1 3924/4885APOBEC3A 3516/4885APOBEC3G 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.